Euglycemic diabetic ketoacidosis caused by empagliflozin complicated by failure to thrive in a geriatric patient
Abstract
Keywords
Full Text:
PDFReferences
Simes BC, MacGregor GG. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician's Guide. Diabetes Metab Syndr Obes. 2019;12:2125-2136. doi: 10.2147/DMSO.S212003. PMID: 31686884; PMCID: PMC6799898.
American Diabetes Association. Standards of Care in Diabetes-2023 Abridged for Primary Care Providers. Clin Diabetes. 2022;41(1):4-31. doi: 10.2337/cd23-as01. Erratum in: Clin Diabetes. 2023;41(2):328. PMID: 36714254; PMCID: PMC9845083.
Larkin HD. FDA Expands Empagliflozin Heart Failure Indication. JAMA. 2022;327(13):1219. doi: 10.1001/jama.2022.3970. PMID: 35380600.
Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. PMID: 32865377.
Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. PMID: 34449189.
Nasa P, Chaudhary S, Shrivastava PK, Singh A. Euglycemic diabetic ketoacidosis: A missed diagnosis. World J Diabetes. 2021;12(5):514-523. doi: 10.4239/wjd.v12.i5.514. PMID: 33995841; PMCID: PMC8107974.
Blau JE, Tella SH, Taylor SI, Rother KI. Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data. Diabetes Metab Res Rev. 2017;33(8):10.1002/dmrr.2924. doi: 10.1002/dmrr.2924. PMID: 28736981; PMCID: PMC5950709.
Selwyn J, Pichardo-Lowden AR. Managing Hospitalized Patients Taking SGLT-2 Inhibitors: Reducing the Risk of Euglycemic Diabetic Ketoacidosis. Diabetology. 2023; 4(1):86-92. https://doi.org/10.3390/diabetology4010010
Pelletier R, Ng K, Alkabbani W, et al. Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews. Ther Adv Drug Saf. 2021;12:2042098621989134. doi: 10.1177/2042098621989134. PMID: 33552467; PMCID: PMC7844442.
Lucero P, Chapela S. Euglycemic Diabetic Ketoacidosis in the ICU: 3 Case Reports and Review of Literature. Case Rep Crit Care. 2018;2018:1747850. doi: 10.1155/2018/1747850. PMID: 30364093; PMCID: PMC6188774.
Sanusi I, Sarnowski A, Russell-Jones D, Forni LG. A potential diagnostic problem on the ICU: Euglycaemic diabetic Ketoacidosis associated with SGLT2 inhibition. J Crit Care. 2020;57:19-22. doi: 10.1016/j.jcrc.2019.12.007. PMID: 32007835.
Sehgal V, Ulmer B. Clinical Conundrums in the Management of Diabetic Ketoacidosis in the Elderly. J Transl Int Med. 2019;7(1):10-14. doi: 10.2478/jtim-2019-0003. PMID: 30997351; PMCID: PMC6463825.
Perry RJ, Rabin-Court A, Song JD, et al. Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats. Nat Commun. 2019;10(1):548. doi: 10.1038/s41467-019-08466-w. PMID: 30710078; PMCID: PMC6358621.
Kayser-Jones J, Schell ES, Porter C, Barbaccia JC, Shaw H. Factors contributing to dehydration in nursing homes: inadequate staffing and lack of professional supervision. J Am Geriatr Soc. 1999;47(10):1187-94. doi: 10.1111/j.1532-5415.1999.tb05198.x. PMID: 10522951.
Pandya N, Hames E, Sandhu S. Challenges and Strategies for Managing Diabetes in the Elderly in Long-Term Care Settings. Diabetes Spectr. 2020;33(3):236-245. doi: 10.2337/ds20-0018. PMID: 32848345; PMCID: PMC7428662.
Bell CL, Lee AS, Tamura BK. Malnutrition in the nursing home. Curr Opin Clin Nutr Metab Care. 2015;18(1):17-23. doi: 10.1097/MCO.0000000000000130. PMID: 25394167.
DOI: http://dx.doi.org/10.22551/2023.39.1002.10248
Copyright (c) 2023 Azeem Rathore, Nidhi Gupta, Cameron Kahn, Dinesh Kadariya
Archive of Clinical Cases is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
ISSN: 2360-6975